EJHaem · 2026
Comparison of Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single-Center Real-World Experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heyman Benjamin, Choi Michael, Kipps Thomas J
Аннотация
INTRODUCTION: The optimal venetoclax-based treatment for patients with relapsed/refractory (R/R) CLL is still unknown, especially for high-risk patients.
METHODS: We performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax-based regimens. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib).
RESULTS: Combination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52-month follow-up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04).
CONCLUSION: This analysis validates, in a real-world academic cohort, that venetoclax-based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL.
METHODS: We performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax-based regimens. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib).
RESULTS: Combination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52-month follow-up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04).
CONCLUSION: This analysis validates, in a real-world academic cohort, that venetoclax-based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL.